MedTrace Logo

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2026-05-08

No results posted yet for this study

Summary

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

Conditions

Interventions

DRUG

VVD-130037

Oral tablets

DRUG

Docetaxel

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Pembrolizumab

IV infusion

Sponsors & Collaborators

  • Vividion Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2030-08-31
Completion
2031-02-28
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05954312 on ClinicalTrials.gov